Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

[1]  M. Shah,et al.  Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022 , 2022, American Journal of Transplantation.

[2]  J. Lewnard,et al.  Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study , 2022, Vaccine.

[3]  Grant D. Huang,et al.  Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022 , 2022, JAMA network open.

[4]  E. Lau,et al.  Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study , 2022, The Lancet.

[5]  V. Wong,et al.  Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Hoshen,et al.  Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge , 2022, The New England journal of medicine.

[7]  E. Lau,et al.  Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study , 2022, The Lancet Infectious Diseases.

[8]  J. Skarbinski,et al.  Natural Language Processing for Improved Characterization of COVID-19 Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System , 2022, JMIR public health and surveillance.

[9]  A. Vasan,et al.  Ensuring Widespread and Equitable Access to Treatments for COVID-19. , 2022, JAMA.

[10]  M. Lipsitch,et al.  Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022. , 2022, MMWR. Morbidity and mortality weekly report.

[11]  R. Gandhi,et al.  Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system , 2022, medRxiv.

[12]  M. Lipsitch,et al.  Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California , 2022, Nature Medicine.

[13]  N. Gronich,et al.  Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Iachan,et al.  Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[15]  J. L. Bernal,et al.  Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study , 2022, Nature Communications.

[16]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[17]  Liyuan Liu,et al.  Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.

[18]  T. Funahashi,et al.  Description and Early Results of the Kaiser Permanente Southern California COVID-19 Home Monitoring Program. , 2021, The Permanente journal.

[19]  G. Krause,et al.  Effect modification of the association between comorbidities and severe course of COVID-19 disease by age of study participants: a systematic review and meta-analysis , 2021, Systematic Reviews.

[20]  N. Jewell,et al.  Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines , 2021, medRxiv.

[21]  J. Skarbinski,et al.  Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization , 2020, Annals of Internal Medicine.

[22]  Jessica G. Burke,et al.  The Development of a Standardized Neighborhood Deprivation Index , 2006, Journal of Urban Health.

[23]  H. Quan,et al.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. , 2004, Journal of clinical epidemiology.

[24]  D. Rubin.  Multiple Imputation After 18+ Years , 1996 .

[25]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .